Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- PMDA Beats Its Targets for Overall Review Time in FY2014
June 24, 2015
- Draft Growth Strategy Embraces Clinical Development Infrastructure, Drops Numerical Target for Sakigake System
June 23, 2015
- 80% Generic Share “at Early Date,” Essential Drug Supplies Join Draft Fiscal Policy Blueprint
June 23, 2015
- PMDA, AMED Plan to Enter Partnership Agreement; Share Information to Promote Commercialization of Seeds
June 23, 2015
- Editor’s Pick: Five Healthcare News Headlines for June 8 - June 21
June 22, 2015
- AMED’s Screening Consortium “Won’t Harm Companies”: Official
June 22, 2015
- AMED to Build Library of Middle-Molecule Compound
June 22, 2015
- No Progress for Wholesalers’ Negative Primary Margin on Sales, Single-Product, Single-Price Deals Stagnant: Ryukaikon
June 19, 2015
- Set Earlier-than-FY2020 Date for 80% Generic Target: Govt Working Group
June 19, 2015
- MOF Generic Target, Reference Pricing Rollout “Impossible”: LDP Panel
June 19, 2015
- First Generics for Plavix to Join NHI Price List on June 19
June 18, 2015
- Ryukaikon to Push Single-Product, Single-Price Deals in New Proposal Due Out Summer
June 18, 2015
- Measures Would Be Necessary if Generic Brands Continue to Increase Due to Joint Development: MHLW Official Jo
June 18, 2015
- PAFSC 2nd Committee Supports Approval of Olanexidine, New Indication for Zosyn
June 18, 2015
- Govt Deregulation Panel Calls for Revisiting 14-Day Prescription Limit
June 17, 2015
- MHLW Designates Ceritinib as Orphan Drug
June 17, 2015
- Govt Working Group Calls for Switching Contract Manufacturing of Long-Listed Drugs to Generic Production
June 16, 2015
- Takeda Slapped with Business Improvement Order over CASE-J
June 12, 2015
- Accession Requirements for ICH Assembly Hammered Out at Fukuoka Confab
June 12, 2015
- LDP Compiles Proposal for Govt Growth Strategy, Including Target for Sakigake System
June 12, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…